Table 3. Recommendations of the National guidelines regarding cancer care adaptations during the pandemic.

Recommended measures	AL	EG	IQ	JO	KSA	KW	LB	MR	OM	SY	TN	UAE	YE
Measures to reduce hospital visits
Favouring oral treatments	+	+	+	+	+	-	+	+	+	+	+	+	+
Avoiding weekly schedules whenever possible	+	+	+	+	+	+	+	+	+	+	+	-	+
Spacing of immunotherapy cycles	+	-	+	+	+	+	+	+	+	+	NA	-	NA
Hypofractionating radiotherapy	-	-	+	+	+	+	+	+	+	+	+	-	NA
Favouring surveillance by teleconsultation in selected situations	+	+	+	+	+	+	+	+	+	-	+	+	-
Postponing non-essential para-clinical examinations	+	+	+	+	+	+	+	+	+	+	+	+	-
Other mesures to reduce complications
Reducing the use of corticoids, whenever possible	+	+	+	-	-	_	+	+	-	+	_	-	-
Using granulocytic growth factors if the risk of febrile neutropenia exceeds certain percentage (10% ?)	+	+	-	-	-	+	+	+	-	+	_	-	-
Site specific recommendations
Breast cancer	-	-	-	+	+	+	+	+	+	+	_	-	_
Lung cancer	-	-	-	+	+	+	+	+	-	+	_	+	-
GI cancers	-	-	-	+	+	+	+	+	+	+	_	-	-
Gynaecologic cancers	-	-	-	+	+	+	+	+	-	+	_	-	-
Urological cancers	-	-	-	+	+	+	+	+	-	+	_	-	-
Head and neck cancers	-	-	-	+	+	+	+	+	-	+	_	-	-

AL: Algeria, EG: Egypt, IQ: Iraq, JO: Jordan, KW: Kuwait, LB: Lebanon, MR: Morocco, OM: Oman, K.S.A: Saudi Arabia, SY: Syria, TN: Tunisia, UAE: United Arab Emirates, YE: Yemen,

N/A: non applicable

+: Item discussed in the country guidelines, -: Item non discussed in the guidelines